Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05567809 · ClinicalTrials.gov registry record
Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 28
- Enrollment target
NCT05567809: Completed study, sponsored by Yale University.
NCT05567809 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05567809 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to help understand how the replacement valve functions over time, both at rest and during exercise.
Primary Outcome
TransAortic Valve Gradient (mmHg) during exercise as assessed by the Echocardiographic Core Laboratory and summarized as peak and mean.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2025-01-21 |
What the finished NCT05567809 record still lists
NCT05567809 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT05567809 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05567809 about?
NCT05567809 is a clinical study titled "Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.". The purpose of this study is to help understand how the replacement valve functions over time, both at rest and during exercise.
What is the current status of trial NCT05567809?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2022-10-25. Estimated completion is 2025-01-21.
Who is sponsoring clinical trial NCT05567809?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI